AB 248
Alternative Names: AB-248Latest Information Update: 20 Jan 2023
At a glance
- Originator Asher Biotherapeutics
- Class Anti-infectives; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action CD8 positive T lymphocyte stimulants; Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Jan 2023 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease, second-line therapy or greater) in USA (IV) (NCT05653882)
- 17 Jan 2023 Phase-I clinical trials in Solid tumours (Monotherapy, Metastatic disease, Late-stage disease, second-line therapy or greater) in USA (IV) (NCT05653882)
- 10 Nov 2022 Asher Biotherapeutics plans a phase Ia/Ib clinical trial for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) (Parenteral) in fourth quarter of 2022